![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Deborah Ramsdell
Deborah Ramsdell has over 30 years of experience in the design and implementation of drug development strategies within thebiopharmaceutical industry. She has been a strategic consultant to biotechnology and pharmaceutical companies and has held senior level executive positions,currently as co-founder of Alopexx Enterprises, an investment and management company, and as President/CEO of Valerion Therapeutics, LLC, an Alopexx Company.
Over the course of her career, she has been responsible for the strategic design and operational oversight of more than 70 drug candidates in the fields of oncology, rare metabolic diseases, dermatology, pain, infectious diseases, transplantation, cardiology, renal diseases, and endocrinology.She is a Master’s level educator with degrees in Biology and Education.
Company:Valerion
Valerion Therapeutics, part of the Alopexx Enterprises portfolio of companies, specializes in the development of therapies for orphan genetic diseases through its proprietary humanized antibody-mediated delivery platform, which enables enhanced intracellular delivery of a range of active therapeutic molecules by way of a transport mechanism present in muscles and neurons. Valerion’s unique product candidates target disease tissues via a novel antibody (3E10) with cell-penetrating properties dependent on a tissue-localized membrane transporter (ENT2). Because the ENT2 transporter is naturally enriched in critical organs (ex. heart and skeletal muscle), Valerion constructs targeted fusion and chemical conjugation products (proteins, drugs and oligos); providing a novel way to treat diseases with limited or no current therapeutic options.
